Outcomes of surgery following chemoradiotherapy for anal cancer: A 10-year retrospective study

• Main Authors: Ioannis Leptidis (Author), Paul A Sutton (Author), Se Hwang Liew (Author), Paul S Rooney (Author)
• Format: Book
• Published: Journal of Surgery and Surgical Research - Peertechz Publications, 2021-04-23.
• Subjects: Retrospective Study
• Online Access: Connect to this object online.

Summary

<p>Introduction: Treatment for Anal cancer is carried out in regional cancer centres but when chemoradiation fails or is ineffective then there is a role for salvage surgery but carries considerable morbidity and mortality. We reviewed clinicopathological outcomes for patients undergoing surgery following Chemoradiotherapy (CRT) for anal cancer. </p><p>Materials and methods: A retrospective review of patient data from patients undergoing surgery for anal cancer from 2008 -2018 was performed. Patients were identified from the anal cancer MDT records and the departmental surgical logbook. </p><p>Results: Forty patients were identified (72.5% female) with a median [IQR] age of 62 [18.25] years. Thirty-three patients underwent APER and seven underwent pelvic exenteration, with 25 (62.5%) having flap reconstruction of the perineum. Post-operative complications were identified in 25 (62.5%) patients, 18 (72%) of which were Clavien-Dindo I-II and 7 (18%) were III-IV. There was one 90-day mortality. The overall 1, 3, and 5-year survival was 76.4%, 47.8% and 35.2% respectively.</p><p>Conclusion: Chemoradiotherapy remains the gold standard for the treatment of anal cancer, with salvage surgery preserved for cases of residual or recurrent disease, or for palliation. We report a median time from completion of CRT to surgery of 12 months, an R0 resection rate of 70%, and 5-year survival of 35.2%. The reason for low 5-year survival requires analysis. Robust prospective data collection is needed to fully quantify outcomes in this important group.</p>

DOI

10.17352/2455-2968.000139